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Junction-mediating and regulatory protein (JMY) is a
novel p53 cofactor that regulates p53 activity during
stress. JMY interacts with p300/CBP, which are ubiqui-
tous transcriptional co-activators that interact with a
variety of sequence-speciﬁc transcription factors, inclu-
ding hypoxia-inducible factor-1a (HIF-1a). In addition,
JMY is an actin-nucleating protein, which, through its
WH2 domains, stimulates cell motility. In this study, we
show that JMY is upregulated during hypoxia in a HIF-
1a-dependent manner. The JMY gene contains HIF-
responsive elements in its promoter region and HIF-1a is
recruited to its promoter during hypoxia. HIF-1a drives
transcription of JMY, which accounts for its induction
under hypoxia. Moreover, the enhanced cell motility and
invasion that occurs during hypoxia requires JMY, as
depleting JMY under hypoxic conditions causes decreased
cell motility. Our results establish the interplay between
JMY and HIF-1a as a new mechanism that controls cell
motility under hypoxic stress.
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JMY (junction-mediating and regulatory protein) was
initially deﬁned through studies on the p300/CBP family
of transcriptional co-activators, which are ubiquitous
transcriptional co-activators that interact with a variety
of sequence-speciﬁc transcription factors, including
p53. During the DNA damage response, JMY along
with the p53 cofactors Strap and PRMT5 are brought
together to inﬂuence p53 activity (Shikama et al., 1999;
Demonacos et al., 2001; Jansson et al., 2008). The
Mdm2 oncoprotein is a key regulator of the p53
response (Marine et al., 2006), and studies identiﬁed
JMY as a new target through which Mdm2 regulates
p53 activity (Coutts et al., 2007).
JMY contains three C-terminal WH2 (Wiskott–
Aldrich syndrome protein (WASp)-homology 2) do-
mains, which facilitate the assembly of actin monomers
into newly formed actin ﬁlaments (Coutts et al., 2009;
Zuchero et al., 2009). Through its ability to inﬂuence
actin nucleation, JMY can enhance cell motility and
invasion, which occurs, in part, through alterations
in cadherin levels (Coutts et al., 2009). Moreover, during
the DNA damage response, JMY becomes more
nuclear, leading to enhanced p53 activity, whereas its
effect on cell motility is diminished (Coutts et al., 2009).
JMY is, thus, a dual-function protein, regulated, in part,
through its subcellular localisation.
Hypoxia triggers an adaptive response and is an
important physiological stress that is highly relevant to
tumour progression. As tumours evolve, oxygen tension
drops, which is associated with angiogenesis, tumour
progression and metastasis (Harris, 2002). Oxygen
homoeostasis is tightly regulated by the transcription
factor hypoxia-inducible factor-1 (HIF-1), a heterodi-
meric complex composed of HIF-1a and HIF-1b
(ARNT) (Wang et al., 1995). HIF-1a levels are kept
low during normoxia, as HIF-1a is rapidly ubiquitinated
and degraded by the 26S proteasome (Kaelin and
Ratcliffe, 2008). During hypoxia, HIF-1a protein is
stabilised and translocates to the nucleus where HIF-1
binds to hypoxia response elements (HREs) in target
genes encoding proteins critical for many important
cellular processes including angiogenesis, proliferation,
apoptosis, glycolysis and invasion (Rankin and Giaccia,
2008; Semenza, 2010).
Many studies have demonstrated a signiﬁcant corre-
lation with hypoxia and metastasis (reviewed in Sullivan
and Graham, 2007). In addition, HIF-1a regulates (both
directly and indirectly) proteins that are key to meta-
static potential, including, for example, E-cadherin,
LOX and endothelin-1 (Erler et al., 2006; Krishnamach-
ary et al., 2006; Spinella et al., 2007). In general,
overexpression of HIF-1a in human tumours is often
associated with poor prognosis and treatment failure,
demonstrating the signiﬁcance of this pathway in cancer
biology (reviewed in (Semenza, 2010)).
As JMY is a stress-responsive protein involved in cell
motility and invasion (Coutts et al., 2009; Zuchero et al.,
2009), we wished to explore the role of JMY in the
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cellular response to hypoxia. Our results indicate that
JMY is upregulated during hypoxia and that its gene is a
novel transcriptional target of HIF-1a. Hypoxia-respon-
sive elements within the JMY proximal promoter are
required for HIF-1a activation under hypoxic condi-
tions. Signiﬁcantly, JMY is required for cell motility and
invasion during hypoxia, most likely mediated through
its ability to foster actin nucleation. The interplay
between JMY and HIF-1a thus deﬁnes a new pathway
for regulating motility under hypoxic conditions.
We examined the levels of JMY in various cell types
growing under hypoxic (2% O2) conditions, and found
that JMY was upregulated (Figure 1a, Supplementary
Figure 1A). Moreover, the induction of JMY during
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Figure 1 JMY is a hypoxia-responsive protein. (a) U2OS cells were incubated under normoxic (N) or hypoxic (2% O2) conditions for
the times indicated before harvesting. Endogenous JMY was detected using anti-JMY antibody L16 (Santa Cruz, Heidelberg, Germany).
HIF-1a was detected using anti-HIF-1a antibody (BD Biosciences, Oxford, UK). Actin was detected using anti-actin antibody (Sigma-
Aldrich, Dorset, UK). * Denotes nonspeciﬁc band (Coutts et al., 2009). (b) MCF-7 cells were treated with deferoxamine (DFO, 100mM) for
the time points indicated before harvesting. JMY and HIF-1a levels are shown. Actin was used as a loading control. (c) MCF-7 (i) or U2OS
(ii) cells were treated with vehicle () or deferoxamine (þ , DFO, 100mM) for 16h before harvesting. Cell extracts were run on SDS–PAGE
and immunoblotted with anti-JMY antibody, and actin was used as a loading control. (d) MCF-7 cells were incubated under either
normoxic (N) or hypoxic (þ ; 2% O2) conditions for 16h before harvesting. Cells were extracted for either protein for immunoblotting (IB)
(upper two panels) or RNA (RT–PCR) (lower two panels). Blots were probed with anti-JMY antibody and PCNA (proliferating cell nuclear
antigen) was used as a loading control. RT–PCR was performed on cDNA obtained from 1mg of RNA from cells using Trizol reagent
(Invitrogen, Paisley, UK) with JMY-speciﬁc primers (Forward 50-gtagagcttttggacttg-30; reverse 50-tctgatctgctcgcatcc-30) and GAPDH-speciﬁc
primers were used as an input control. (e) HCT116 HIF-1aþ /þ (WT) or HIF-1a/ were grown under normoxic (N) or hypoxic (2% O2)
conditions for 16h before harvesting. Blots were probed with JMY and HIF-1a antibodies. Actin was used as a loading control. (f) MCF-7
cells were transfected with 25 nM of control (non-targeting control #2, Dharmacon/Thermo Scientiﬁc, Epsom, UK) or HIF-1a siRNA
(Santa Cruz) using oligofectamine (Invitrogen). After 48h, cells were treated with DFO (100mM) and left for a further 24h before harvesting.
Blots were probed with JMY and HIF-1a antibodies. Actin was used as a loading control. (g) (i) MCF-7 cells were treated with vehicle ()
or DFO (þ ), 100mM) with (þ ) or without () HIF-1a inhibitor (3-(2-(4-adamantan-1-yl-phenoxy)-acetylamino)-4-hydroxybenzoic acid
methyl ester, Merck/Calbiochem, Nottingham, UK; inhibitor; 30mM) for 16h before harvesting. Blots were probed with JMY and HIF-1a
antibodies, and actin was used as a loading control. (ii) Luciferase reporter assays were performed using U2OS cells as previously described
(Chan et al., 2001). Cells were transfected, using GeneJuice (Merck), with 200 ng VEGF–luciferase construct (a kind gift from Peter
Ratcliffe, University of Oxford) along with 400ng empty vector () or HIF-1a expression vector (a kind gift from Shoumo Bhattacharya,
University of Oxford) for 48h before harvesting. Transfections also included 100ng of pCMV-b-galactosidase (b-gal) plasmid as an internal
control. Cells were treated as in (i) with HIF-1a inhibitor for 16 h before harvesting. Graph represents fold luciferase activity after
normalising for b-gal, which was used as a measure of transfection efﬁciency. Blots underneath represent HIF-1a input levels.
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hypoxia occurred by 2 h, reﬂecting the induction of
HIF-1a at a similar time point (Figure 1a). Additionally,
JMY was upregulated after growth under a variety of
oxygen concentrations, including anoxia (Supplemen-
tary Figures 1A and B), indicating JMY is sensitive to
oxygen tensions ranging from mild (2–0.5%) to severe
(o0.02%) hypoxia. Moreover, treating cells with
deferoxamine (DFO), an iron chelator, which mimics
certain properties of hypoxia by upregulating HIF-1a
(Wang and Semenza, 1993), resulted in upregulation of
JMY protein (Figures 1b and c i,ii), in a similar manner
as HIF-1a (Figure 1b). Of note, JMY mRNA levels
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were induced along with JMY protein levels under
hypoxia (Figure 1d). Together these data indicate that
JMY is upregulated during hypoxia and further suggest
that its transcriptional regulation is hypoxia-responsive.
As JMY is regulated at the transcriptional level
during hypoxia and its regulation mimicked that seen
with HIF-1a, we explored the possibility that HIF-1a
might be involved in regulating JMY. Initially, we
examined JMY levels during hypoxia in HCT116
cells that are HIF-1a/ (Dang et al., 2006) compared
with normal counterparts, HIF-1aþ /þ . Interestingly,
JMY was not upregulated during hypoxia in HCT116
HIF-1a/ cells, but was in the parental, HIF-1aþ /þ ,
cells (Figure 1e). This suggested that JMY upregulation
during hypoxia relies on HIF-1a. To conﬁrm this, using
another cell system, MCF-7 cells were depleted of HIF-
1a by siRNA treatment and JMY levels examined
during hypoxic conditions. Indeed, depletion of HIF-1a
under DFO treatment prevented upregulation of JMY
(Figure 1f). To provide further evidence that JMY
upregulation relies on HIF-1a activity, cells were
treated with a HIF-1a inhibitor (3-(2-(4-adamantan-1-yl-
phenoxy)-acetylamino)-4-hydroxybenzoic acid methyl
ester), which prevents HIF-1a transcriptional activity
and reduces HIF-1a protein levels (Lee et al., 2007;
Figure 1gii). Treating cells with DFO resulted in an
upregulation of both JMY and HIF-1a (Figure 1gi),
whereas co-treatment with the HIF-1a inhibitor reduced
the upregulation of both JMY and HIF-1a (Figure 1gi).
Together these data conﬁrm that JMY requires HIF-1a
activity for upregulation during hypoxia.
Inspection of the upstream promoter region of JMY
identiﬁed several putative HRE that closely resembled
the canonical sequence A/G CGTG as well as a broader,
though less well-deﬁned, sequence BACGTSSK (B¼T/
G/C; S¼G/C; K¼T/G (Rankin and Giaccia, 2008;
Semenza, 2010)), in the proximal JMY promoter
(Figure 2a). Interestingly, six putative HREs were
identiﬁed in the human JMY promoter (Figures 2a
and ci). Of these, the cluster of ﬁve is highly conserved
across different species, whereas a more distal HRE is
only found in the human JMY promoter (Figure 2b).
Primers were designed to encompass this region for use
in chromatin immunoprecipitation (Figure 2a) to
explore the recruitment of HIF-1a to the JMY
promoter. Indeed, HIF-1a was recruited to the JMY
promoter under DFO treatment (Figure 2d i,ii), sup-
porting the existence of functional HREs in this region.
To further study the regulation of this region by HIF-
1a, the JMY promoter (399 to þ 32, encompassing all
six HREs and 174 to þ 32, encompassing ﬁve
proximal HREs) was cloned into pGL3-basic in order
to perform luciferase assays (Figure 2cii). HIF-1a
activated both reporter constructs (Figure 2e), conﬁrm-
ing the ability of HIF-1a to regulate JMY expression.
Additionally, HIF-1a regulation of the JMY promoter
occurred in a dose-responsive manner (Figure 2f).
To establish the functional signiﬁcance of HIF-1a in
regulating JMY transcription, the ﬁve highly conserved
individual HREs (1–5; Figure 2cii) were each mutated
and the ability of HIF-1a to transcriptionally activate
the mutated JMY promoter constructs was assessed
in luciferase assays. Mutating the ﬁve HREs resulted
in near complete ablation of HIF-1a activation of
the JMY promoter (Supplementary Figure 1C). Inter-
estingly, mutating HRE-1 and -4 consistently resulted
in enhanced activation of the JMY promoter by
HIF-1a (Figure 2g). Mutating HRE-3 had the most
consistent effect in terms of reducing HIF-1a activation
of the JMY promoter, whereas loss of HRE-2 and -5
also resulted in inhibition of HIF-1a activity
(Figure 2g). Together these data show that JMY is a
HIF-1a responsive gene and deﬁnes the mechanism
involved.
Figure 2 JMY promoter is HIF-1a-responsive element. (a) Sequence of the human JMY 50 promoter region. Grey shading indicates
exon 1. Underlined ATG is initiating methionine. Blue shading indicates primers used for chromatin immunoprecipitation (ChIP)
analysis. The putative HREs are shaded in red. (b) Line-up shows the conservation of the JMY promoter around the HREs. m, mouse,
h, human, b, bull. Red shading indicates HREs. (c) (i) Comparison of JMY HREs to consensus. (ii) Schematic represents the two
regions of the JMY promoter cloned into pGL3-basic for reporter assays. Base pair numbering is relative to the transcription start site.
Grey-shaded ovals represent individual HREs and numbers 1–5 represent the individual HREs mutated in (g). (d) Chromatin
immunoprecipitation was performed on chromatin from MCF-7 cells treated with either vehicle () or 100mM deferoxamine (DFO,
þ ) for 16 h as previously described (Zalmas et al., 2008). HIF-1a was immunoprecipitated with anti-HIF-1a antibody (HIF). ns,
nonspeciﬁc control IgG immunoprecipitation. Inputs represent non-immunoprecipitated chromatin. Immunoprecipitated chromatin
was puriﬁed using Qiaquick PCR puriﬁcation kit (Qiagen, Crawley, UK) according to the manufacturer’s instructions. PCR was
performed on chromatin using JMY-speciﬁc primers (JMYCHIPF1 50-gcggcaacacgctacttct-30; JMYCHIPF2 50-cacctgccactctcatcgc-30;
JMYCHIPR2 50-gaacccgtctcctaaactctg-30). (i) PCR, on chromatin, performed with primers encompassing six HREs (JMYCHIPF1/
JMYCHIPR2). (ii) PCR, on chromatin, performed with primers encompassing ﬁve HREs (JMYCHIPF2/JMYCHIPR2).
(e) Luciferase reporter assays were performed using U2OS cells as previously described (Chan et al., 2001). Cells were transfected
with 100 ng JMY promoter luciferase constructs, as denoted along either with 400 ng empty vector () or with HIF-1a expression
vector (þ ) for 48 h before harvesting. Graph represents fold luciferase activity after normalising for b-galactosidase (b-gal), which was
used as a measure of transfection efﬁciency. Blots underneath represent HIF-1a input levels. (f) Luciferase reporter assays were
performed using U2OS cells. Cells were transfected with 100 ng JMY promoter luciferase construct 174 to þ 32, along either with
empty vector () or with the appropriate amount of HIF-1a expression vector (þ ), as denoted. Graph represents fold luciferase
activity after normalising for b-gal, which was used as a measure of transfection efﬁciency. Blot underneath represents HIF-1a input
levels. (g) Luciferase reporter assays were performed using U2OS cells transfected with 100 ng JMY promoter luciferase construct
174 to þ 32, along either with 400 ng empty vector () or with HIF-1a expression vector (þ ) for 48 h before harvesting. Graph
represents fold luciferase activity after normalising for b-gal, which was used as a measure of transfection efﬁciency. WT, wild-type
JMY promoter 174 to þ 32, 1–5 denotes the HRE that was mutated (see (cii). HREs 1–5 (see c)) were mutated to AAAAA using
QuickChange Site-directed mutagenesis kit (Agilent Technologies, Stockport, UK) according to the manufacturer’s instructions.
Blot underneath represents HIF-1a input levels. A full colour version of this ﬁgure is available at the Oncogene journal online.
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Figure 3 JMY inﬂuences motility during hypoxia. (a) (i) MCF-7 cells were treated with 25nM non-targetting (con) or JMY siRNA (Coutts
et al., 2009) for 72h before performing scratch wound assays. Scratch wound assays were performed on conﬂuent cells as previously
described (Coutts et al., 2009). Photographs were taken immediately after wounding (time 0), and after 16h incubation under 2%O2. Graph
in (ii) represents percentage wound closure after 16h. Values represent mean±s.e.m., *Po0.001, Student’s t-test, n¼ 3 independent
experiments. Blots underneath represent the degree of JMY knockdown. (iii) MCF-7 cells were treated as in (i) for 72h. Cells were re-plated
into CIM-plate 16 (Roche Diagnostics, GmbH, Germany) with 8mm pores. These specially designed ‘transwells’ measure capacitance on the
underside of the dividing membrane (RTCA DP instrument, Roche Diagnostics). In total, 40 000 cells in serum-free media were seeded into
the upper chamber, and the lower chamber contained 10% FBS-DMEM as a chemoattractant. Experiments were carried out using the
RTCA DP instrument (Roche Diagnostics), which was placed in a humidiﬁed incubator maintained at 37 1C with 3% O2/5% CO2. The
electronic sensors provided a continuous and quantitative measurement of the cell index (reﬂecting impedence, which depends on the
number of attached cells; for example, lower cell index reﬂects that less cells migrated) in each well. The CIM-plate 16 was monitored every
15min for 10h. (b) (i) MDA-MB-231 cells were treated as in (a) and scratch wound assays were performed. Graph represents percentage
wound closure after 16h. Values represent mean±s.e.m., *Po0.005, Student’s t-test, n¼ 2 independent experiments. Blots underneath
represent the degree of JMY knockdown. (ii) Cells were treated as in (i) before performing migration assays as outlined in (aiii). (c) HEK 293
cells were treated with control (con) or JMY siRNA for 72h before performing scratch wound assays followed by treating cells for an
additional 16h with 100mM deferoxamine (DFO). Graph represents percentage wound closure after 16h. Values represent mean±s.e.m.,
*Po0.001, Student’s t-test, n¼ 2 independent experiments. Blots underneath represent the degree of JMY knockdown. (d) Inducible stable
JMY overexpressing U2OS cells (Coutts et al., 2009) treated with vehicle control () or doxycycline (þ , dox, 100mg/ml) along with 100mM
deferoxamine (DFO) at the time of performing scratch wound assays. Graph represents percentage wound closure after 16h. Values
represent mean±s.e.m., *Po0.05, Student’s t-test, n¼ 2 independent experiments. Blot underneath represents inducible JMY levels.
(e) (i) U2OS stable-inducible JMY cells (JMY) or an empty vector control cell line (vector) (Coutts et al., 2009) were treated with 100mM
deferoxamine (DFO) for 22h along with doxycycline (1mg/ml). Blots were probed with anti-JMY and anti-HIF-1a antibodies, and actin was
used as a loading control. (ii) In total, 1 105 U2OS stable-inducible wild-type JMY cells (JMY) or empty vector control cells (vector),
treated as in (i), were plated on both control and Matrigel chambers and treated with 100mM DFO. Matrigel chamber cell migration assays
were performed using Matrigel Invasion Chambers (BD Biosciences) with an 8mm pore size according to the manufacturer’s protocol. Cells
were allowed to invade for 22h before ﬁxing and staining with propidium iodide to visualise nuclei. Results are representative of two
individual experiments. Graph in (iii) represents percentage of cells invaded with DFO treatment. A full colour version of this ﬁgure is
available at the Oncogene journal online.
JMY is a HIF-1a target
AS Coutts et al
4839
Oncogene
We explored the role of JMY in cell motility during
hypoxia. When JMY was depleted (through treatment
with siRNA) from MCF-7 human breast cancer cells,
there was a marked decrease in their ability to migrate
into newly formed wounds (Figure 3ai). Although the
control siRNA-treated cells showed an approximately
37% closure after 24 h, the JMY siRNA-treated cells
showed only an approximately 17% closure after 24 h
(Figure 3aii). Similar results were also observed with a
variety of other cell types, including MDA-MB-231
and HEK 293 (Figure 3b and Supplementary Figure
2A). To gain further support, cell migration was
measured in real-time where depletion of endogenous
JMY resulted in decreased migration kinetics (Figures
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Figure 4 JMY localises with actin during hypoxia. (a) U2OS cells were plated onto 13mm coverslips and transfected with HA-JMY
(Coutts et al., 2009). 24 h later, coverslips were grown under the oxygen concentrations denoted for 16 h before ﬁxing and processing
for immunoﬂuorescence. Immunoﬂuorescence was performed as previously described (Coutts et al., 2009). JMY was detected with
anti-HA antibody HA11 (Covance, Leeds, UK) and phalloidin was used to stain F-actin. DAPI (4060-diamidino-2-phenylindole) was
used to visualise nuclei. The arrowheads indicate regions of JMY and actin colocalisation. Enlarged region shows JMY and actin
colocalisation under hypoxia. (b) Triplicate experiments in (i) U87 and (ii) MDA-MB-231 xenografts comparing three controls
with three bevacizumab (anti-VEGF mAb) tumours. JMY expression was measured by Affymetrix Plus2 arrays (Affymetrix, High
Wycombe, UK) in (i) and Affymetrix Human Exon 1 ST arrays in (ii). Data were RMA processed, quantile normalised and logged
base2. Plus2 arrays: graph represents mean±s.e.m., P¼ 0.028, Student’s t-test. Exon arrays: graph represents mean±s.e.m., for each
exonic probe set. Analysis of variance was performed including treatment (bevacizumab versus control) as factor and probe set as
random effect. F¼ 79.3, P¼ 2.E-6. Only core exonic probe sets are shown. Xenografts: all protocols were carried out under the
Home Ofﬁce regulations (Li et al., 2007). The tumour cells (107) were implanted into 6- to 8-week-old female BALB/c SCID mice
(Harlan Sprague–Dawley, Inc., Indianapolis, IN, USA) s.c. with 50ml of cell suspension with an equal volume of Matrigel (BD Bioscience).
Each group consisted of ﬁve mice. Tumour growth was monitored and measured using calipers. Tumour volume was calculated from a
formula (V¼LWH 0.52). Bevacizumab was injected i.p. every 3 days at a dose of 10mg/kg, starting when the tumour reached
150mm3. Tumour samples were collected at the end of experiments and were freshly frozen in liquid N2. RNA extraction from
the tumour samples was performed as described previously (Li et al., 2007). Microarray analyses were carried out at the CRUK
microarray services centre in Manchester. (iii) Immunostaining on tumour sections from U87 xenografts treated as described above.
Tumour-bearing mice were injected i.v. with 2mg pimonidazole (Hypoxylprobe-1) in 0.9% saline at 30min before killing of the mouse
(Li et al., 2007) and staining for pimonidazole was performed using the Hypoxyprobe-1 kit (Chemicon, Millipore, Watford, UK)
according to the manufacturer’s instructions. HIF-1a staining was performed as previously described (Biswas et al., 2010). (c) Model
depicts function of JMY during hypoxia. In hypoxic conditions, JMY levels are enhanced through HIF-1-dependent transcriptional
activation of JMY. JMY inﬂuences the motility and invasion through its ability to nucleate cytoplasmic actin.
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3aiii and bii). Importantly, the kinetic analysis demon-
strated that JMY depletion inhibits migration as early as
2 h (Figures 3aiii and bii), which thus rules out the
inﬂuence of proliferation on cell motility.
Additionally, under DFO treatment, JMY-depleted
cells showed a signiﬁcant decrease in their ability
to migrate into newly formed wounds (Figure 3c).
Consistent with this observation, overexpression of
JMY under DFO treatment augmented cell motility
(Figure 3d). Real-time measurement of cell migration
demonstrated that at early time points the induction of
ectopic JMY resulted in a signiﬁcant enhancement of
migration during hypoxia (Supplementary Figure 2B).
Moreover, ectopic JMY (Figure 3ei) augmented inva-
sion through Matrigel (Figure 3e ii, iii). Together these
data demonstrate that JMY is necessary for hyoxia-
regulated cell motility.
The ability of JMY to inﬂuence cell motility during
the DNA damage response is, in part, regulated by its
localisation (Coutts et al., 2009). Thus, we wished to
examine the localisation of JMY during hypoxia.
In unperturbed normoxic cells (20% O2) JMY was
present in the cytoplasm, where it localised with actin
(Figure 4a). During hypoxia, JMY was also able to
colocalise with actin at the cell periphery, and similar to
normoxic conditions, JMY remained primarily cyto-
plasmic (Figure 4a and Supplementary Figure 3). Thus,
the presence of JMY at actin-containing structures
under hypoxic conditions is consistent with its role in
regulating cell motility (Figure 4b).
To explore the in vivo regulation of JMY, we
examined JMY levels in xenografts from bevacizumab
(anti-VEGF)-treated tumours, which increases intratu-
moral hypoxia (Ferrara et al., 2005; Rapisarda et al.,
2009). Importantly, this correlated with a signiﬁcant
upregulation of JMY (Figure 4b i,ii). As anticipated,
elevated HIF-1a levels and intratumoral hypoxia, as
assessed by anti-HIF-1a and pimonidazole staining,
were apparent (Figure 4biii). Thus, these data demon-
strate that in hypoxic tumours in vivo JMY expression
coincides with increased HIF-1a activity.
Our study demonstrates an important and novel link
between the actin-nucleating factor JMY and HIF-1a.
JMY is a novel HIF-1a target gene that mediates cell
motility and invasion during hypoxia (Figure 4c). The
ability of HIF-1a to activate JMY under hypoxic
conditions provides a mechanism that maintains JMY
at sufﬁcient concentrations in hypoxic cells to facilitate
cell motility. Given the enhanced cell motility that
occurs under hypoxia (Sullivan and Graham, 2007), it
makes sense that actin nucleation factors that augment
cell motility, like JMY, should be responsive to such
stimuli. Importantly, this study deﬁnes another pathway
through which hypoxia and the DNA damage response
can be integrated and suggests that JMY may be a
clinically relevant target during tumour progression.
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